Hyperfine has received FDA approval for the world’s first bedside MR system, creating new possibilities for hospitals seeking point-of-care imaging with a system the company says is 20 times cheaper, 10 times lighter and consumes 35 times less power than fixed conventional MR solutions.
The system, which is equipped with a .064 Tesla magnet — significantly lower than that of a standard scanner — requires no shielding, was designed with the nearly 90% of the world lacking access to MR in mind and may also prove beneficial for patients that are too fragile to move from the bedside, as well as ER patients who complain of headaches or dizziness. It is controlled via a wireless tablet, and is expected to benefit a number of specialties, says Chris Ward, head of marketing for Hyperfine.
"In hospitals, the first applications most people think of is pediatrics and avoiding the ionizing radiation of CT," he told HCB News. "Another is intensive care where MR would be used if only it were readily accessible for some of the sickest, most fragile and hard-to-transport patients in the hospital. We've had a big reception from emergency medicine where time matters and MR essentially goes under-ordered because it is typically far away from the ED and it is often backlogged. From there, we can extend to Hyperfine use outside of the hospital such as urgent care clinics, naval and cruise ships at sea, sports medicine applications and more."
Prior to its approval by the FDA, thousands of scans were performed with the system
as part of investigational partnerships at Yale New Haven University, Penn Medicine, Good Samaritan Hospital Long Island, New York Presbyterian Brooklyn Methodist Hospital, and Brown University.
A preliminary study funded by Hyperfine and the American Heart Association Collaborative Science Award found that portable, low-field MR systems provide safe and practical ways for obtaining accurate brain images at a patient’s bedside. Eighty-five stroke patients received such care from the Hyperfine system within seven days of the onset of their symptoms, with exam time averaging about 30 minutes. Most patients completed the entire exam, with the exception of five who could not fit into the 30-centimeter opening of the MR machine. Six patients also experienced claustrophobia, which halted their tests. No significant adverse events were reported, however, and no metals had to be removed from the room either, due to the device’s low-field magnet.
Dr. Kevin Sheth, senior author and chief physician of the division of neurocritical care and emergency neurology at Yale School of Medicine and Yale New Haven Hospital in Connecticut, told HCB News that he can see the system used frequently to assess "lots of acute neurological injuries, like head trauma and brain hemorrhages."
He adds that the next steps for further building up the technology are scanning more patients, improving image quality, using the devices in multiple settings and using machine learning to extract as much meaningful information as possible. "It's still early. We are in the process of imaging these pathologies when they are first presented to the emergency department."
Ward says any next steps require the help of Hyperfine's collaborators. "Today is a major milestone for Team Hyperfine, but there's a lot more our current platform can do, so we are pursuing additional indications, working with our clinical research partners," said Ward. "We have ideas and active efforts on several fronts. And we need to achieve regulatory clearance in additional countries."
Hyperfine unveiled the system
at the 2019 Radiological Society of North America and it will be on display once more at the International Stroke Conference in Los Angeles, from February 19-21; NVIDIA GPU Technology Conference in San Jose, from March 23-26; and at the American Society of Neuroradiology in Las Vegas from May 30 – June 4, 2020.